PTC Therapeutics | PTCT - Current Assets


PTC Therapeutics reported $2.25B in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.1B 33.9M Mar/2026
Alnylam Pharmaceuticals USD 4.22B 168.65M Mar/2026
Amgen USD 31.48B 2.42B Mar/2026
BioCryst Pharmaceuticals USD 373.62M 30.72M Mar/2026
Biogen USD 9.19B 216.3M Mar/2026
BioMarin Pharmaceutical USD 4.61B 651.58M Mar/2026
Cytokinetics USD 839.46M 77.51M Mar/2026
Daiichi Sankyo JPY 2.1T 218.5B Dec/2025
Enanta Pharmaceuticals USD 198.68M 5.65M Dec/2025
Gilead Sciences USD 18.64B 1.25B Mar/2026
Incyte USD 5.48B 460.36M Mar/2026
Ionis Pharmaceuticals USD 2.94B 52M Mar/2026
Ironwood Pharmaceuticals USD 332.29M 58.11M Mar/2026
Karyopharm Therapeutics USD 103.15M 13.4M Dec/2025
Novartis USD 26.61B 3.85B Mar/2026
Pfizer USD 42.82B 76M Mar/2026
PTC Therapeutics USD 2.25B 19.94M Mar/2026
Puma Biotechnology USD 143.58M 7M Sep/2025
Roche Holding CHF 38.73B 3.03B Dec/2025
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Sarepta Therapeutics USD 2.31B 228.06M Mar/2026
TG Therapeutics USD 1.09B 456.2M Mar/2026
Ultragenyx Pharmaceutical USD 657M 294M Mar/2026
Vertex Pharmaceuticals USD 11.73B 529.3M Mar/2026
Xencor USD 482.85M 116.97M Mar/2026